Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
Login
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

Ad26.ZEBOV-G

Brand and Other Names: Zabdeno
Mechanism of Action:
Indications:
Route:
Dose:
Adverse Reactions:
Contraindication:
Warnings and Precautions:
Description:

Not FDA-approved in the US; approved in EU in July 2020 (European Medicines Agency (EMA)) 

GOOGLE OVERVIEW

Ad26.ZEBOV-G, also known as Zabdeno®, is a vaccine for Ebola virus disease. It uses a non-replicating adenovirus serotype 26 vector to deliver the glycoprotein (GP) of the Ebola virus (Mayinga variant). It is administered as a 0.5 mL intramuscular injection. It is part of a two-dose heterologous regimen, with the second dose typically being MVA-BN-Filo. 
 
Here's a more detailed breakdown:
  • Type of Vaccine: Ad26.ZEBOV-G is an adenovirus-vectored vaccine. 
     
  • Target Pathogen: It targets the Ebola virus, specifically the Mayinga variant. 
     
  • Mechanism: The vaccine uses a non-replicating adenovirus vector to deliver the Ebola virus glycoprotein gene into cells. This triggers an immune response against the Ebola virus without causing infection. 
     
  • Administration: It is administered as an intramuscular injection. 
     
  • Two-Dose Regimen: Ad26.ZEBOV-G is typically used in a two-dose regimen, with the second dose being MVA-BN-Filo (a modified vaccinia Ankara-vectored vaccine), administered 56 days apart. 
     
  • Approval: This vaccine regimen (Ad26.ZEBOV-G followed by MVA-BN-Filo) is approved in the EU for use in children aged one year and older under "exceptional circumstances". 
See package insert for full prescribing information.